ClinicalTrials.gg
Not yet recruitingNCT07558707Updated Apr 30, 2026

Fexuclue for Prevention of NSAIDs-Induced Peptic Ulcer in Real-World Practice

An observational study in Peptic Ulcer and NSAID-Induced Peptic Ulcer, sponsored by Daewoong Pharmaceutical Co. LTD.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Daewoong Pharmaceutical Co. LTD. · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
7,000
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies in Peptic Ulcer with a site in Korea, Republic of — 4 open to participants now, 5 under way, 3 of them phase 3. Peptic Ulcer · Korea, Republic of.

Started
2026
with 1 other
Observational
3 of 19
1 open now
Registered
18th of 19
by date
Lead sponsor
3 of 19
Daewoong Pharmaceutical Co. LTD.

Among the 19 studies in Peptic Ulcer with a site in Korea, Republic of, this one is one of 2 that started in 2026, is one of 3 observational ones, and was the 18th registered.

Peptic Ulcer

146 studies on the registry are indexed under Peptic Ulcer; 25 are open to participants now.

Browse Peptic Ulcer studies →

Open to participants now

4 of the 19 studies in Peptic Ulcer with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 18 Peptic Ulcer studies recruiting now, 11 (61%) set no upper age limit and 7 (39%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Peptic Ulcer with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study is a prospective, multi-center, observational study to evaluate the efficacy and safety of Fexuclue Tablet 20 mg in patients requiring prevention of NSAIDs-induced peptic ulcer in real-world clinical practice in Korea.

Patients receiving NSAIDs and requiring gastroprotective therapy will be enrolled and followed prospectively. The study will assess patient-reported outcomes (PROs) related to gastrointestinal symptoms, as well as safety outcomes.

Read the detailed description

This study is a prospective, multi-center, observational study conducted in Korea to evaluate the efficacy and safety of Fexuclue Tablet 20 mg in patients requiring prevention of NSAIDs-induced peptic ulcer in routine clinical practice.

Adult patients receiving NSAIDs who require prevention of peptic ulcer will be enrolled after providing written informed consent. Treatment with Fexuclue Tablet will be prescribed based on the physician's clinical judgment in accordance with approved labeling.

The study will primarily evaluate patient-reported outcomes (PROs) related to gastrointestinal symptoms using electronic PRO (ePRO) questionnaires. Assessments will be conducted at baseline and at approximately 2, 4, 8, and 12 weeks after treatment initiation.

Safety will be assessed by monitoring adverse events. This study aims to provide real-world evidence on symptom prevention and improvement in patients requiring NSAIDs-induced peptic ulcer prevention.

03

Conditions studied

  • Peptic Ulcer
  • NSAID-Induced Peptic Ulcer

Browse trials for

Keywords

  • NSAIDs
  • Fexuprazan
  • PRO
  • Real-World
  • Peptic Ulcer Prevention
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

This study will enroll adult patients aged 19 years or older who require prevention of NSAIDs-induced peptic ulcer in routine clinical practice in Korea. Eligible patients are those who are prescribed Fexuclue Tablet 20 mg based on the physician's clinical judgment.

Patients receiving NSAIDs and requiring gastroprotective therapy will be prospectively enrolled from multiple centers under real-world conditions. Treatment decisions will be made according to routine clinical practice.

Patients with contraindications to the study drug or those deemed inappropriate by the investigator will be excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥19 years
  • Patients requiring NSAIDs therapy
  • Patients requiring prevention of NSAIDs-induced peptic ulcer
  • Patients prescribed Fexuclue Tablet 20 mg
  • Patients who provide written

Exclusion criteria

Exclusion Criteria:

  • to Fexuclue or its components
  • Severe hepatic impairment
  • Pregnant or breastfeeding women
  • Patients considered inappropriate by investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
7,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Fexuclue Treatment Group

    Patients requiring prevention of NSAIDs-induced peptic ulcer who are prescribed Fexuclue Tablet 20 mg in routine clinical practice.

06

What researchers measure

Primary outcomes

  1. Proportion of Patients with Peptic Ulcer Symptom Occurrence at Week 2

    Peptic ulcer symptoms will be assessed using a study-specific patient-reported outcome (PRO) questionnaire consisting of 6 symptom items. Each symptom is scored on a scale from 0 (none) to 4 (very severe). Symptom occurrence is defined as: Increase of ≥1 point in at least one symptom item compared to baseline Includes: New occurrence in asymptomatic patients Worsening in symptomatic patients The proportion (%) of patients with symptom occurrence at Week 2 will be calculated.

    Time frame: Week 2

Secondary outcomes

  1. Proportion of Patients with Peptic Ulcer Symptom Occurrence at Week 4

    Peptic ulcer symptom occurrence is defined using the same criteria as the primary endpoint (≥1-point increase in at least one symptom item from baseline). The proportion (%) of patients with symptom occurrence will be calculated at Week 4

    Time frame: Week 4

  2. Proportion of Patients with Peptic Ulcer Symptom Occurrence at Week 8

    Peptic ulcer symptom occurrence is defined using the same criteria as the primary endpoint (≥1-point increase in at least one symptom item from baseline). The proportion (%) of patients with symptom occurrence will be calculated at Week 8

    Time frame: Week 8

  3. Proportion of Patients with Peptic Ulcer Symptom Occurrence at Week 12

    Peptic ulcer symptom occurrence is defined using the same criteria as the primary endpoint (≥1-point increase in at least one symptom item from baseline). The proportion (%) of patients with symptom occurrence will be calculated at Week 12

    Time frame: Week 12

  4. Change From Baseline in Total Score of Patient-Reported Gastrointestinal Symptom Questionnaire at Week 2

    Gastrointestinal symptoms will be assessed using a study-specific PRO questionnaire with 6 symptom items, each scored from 0 (none) to 4 (very severe). The total score ranges from 0 to 24, with higher scores indicating more severe symptoms. The outcome measure is defined as the change from baseline in total score at each time point.

    Time frame: Week 2

  5. Change From Baseline in Total Score of Patient-Reported Gastrointestinal Symptom Questionnaire at Week 4

    Gastrointestinal symptoms will be assessed using a study-specific PRO questionnaire with 6 symptom items, each scored from 0 (none) to 4 (very severe). The total score ranges from 0 to 24, with higher scores indicating more severe symptoms. The outcome measure is defined as the change from baseline in total score at each time point.

    Time frame: Week 4

  6. Change From Baseline in Total Score of Patient-Reported Gastrointestinal Symptom Questionnaire at Week 8

    Gastrointestinal symptoms will be assessed using a study-specific PRO questionnaire with 6 symptom items, each scored from 0 (none) to 4 (very severe). The total score ranges from 0 to 24, with higher scores indicating more severe symptoms. The outcome measure is defined as the change from baseline in total score at each time point.

    Time frame: Week 8

  7. Change From Baseline in Total Score of Patient-Reported Gastrointestinal Symptom Questionnaire at Week 12

    Gastrointestinal symptoms will be assessed using a study-specific PRO questionnaire with 6 symptom items, each scored from 0 (none) to 4 (very severe). The total score ranges from 0 to 24, with higher scores indicating more severe symptoms. The outcome measure is defined as the change from baseline in total score at each time point.

    Time frame: Week 12

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Apr 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2026
First posted
Apr 30, 2026
StartEst.
Apr 30, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07558707
Responsible party
Sponsor
First posted
Apr 30, 2026
Start date
Apr 30, 2026 (estimated)
Primary completion
Apr 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 30, 2026

Study contacts

SoHeui Kim
Contact
2210325@daewoong.co.kr
82-10-2994-5887

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion